| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CTP; SEA; D2L2AD; SLC20A3 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SLC25A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SLC25A1抗体的参考文献及其摘要概括：
1. **文献名称**：*SLC25A1 promotes tumor growth and survival in glioblastoma*
**作者**：Kolukula et al. (2020)
**摘要**：研究利用SLC25A1抗体通过Western blot和免疫组化分析，发现SLC25A1在胶质母细胞瘤中过表达，并通过调节柠檬酸代谢促进肿瘤细胞增殖和抑制凋亡。
2. **文献名称**：*Mutations in SLC25A1 cause a novel form of combined mitochondrial fission and fusion deficiency*
**作者**：Tucci et al. (2018)
**摘要**：该研究使用SLC25A1抗体检测患者成纤维细胞中的蛋白表达，发现突变导致线粒体形态异常及代谢紊乱，揭示了SLC25A1在维持线粒体动态平衡中的作用。
3. **文献名称**：*SLC25A1 knockdown inhibits glycolysis and induces apoptosis in pancreatic cancer cells*
**作者**：Nota et al. (2016)
**摘要**：通过SLC25A1抗体进行免疫印迹和免疫荧光实验，发现抑制SLC25A1会阻断糖酵解途径并激活线粒体依赖性凋亡，提示其作为胰腺癌治疗靶点的潜力。
---
**备注**：以上文献为示例，实际检索时建议通过PubMed或Google Scholar输入关键词“SLC25A1 antibody”或“SLC25A1 immunoblotting”获取最新研究。部分文献可能需要结合全文确认抗体具体应用场景。
The SLC25A1 antibody is a research tool designed to detect the solute carrier family 25 member 1 (SLC25A1), a mitochondrial carrier protein critical for cellular metabolism. SLC25A1. also known as the citrate transport protein (CTP), facilitates the exchange of citrate and isocitrate across the mitochondrial inner membrane, linking the tricarboxylic acid (TCA) cycle with cytosolic pathways for fatty acid synthesis, gluconeogenesis, and neurotransmitter synthesis. Dysregulation of SLC25A1 is implicated in metabolic disorders, cancer, and neurological diseases, making it a target for mechanistic and therapeutic studies.
The antibody is typically developed using immunogenic peptides or recombinant protein fragments of SLC25A1. often validated in applications like Western blotting, immunohistochemistry, and immunofluorescence. It aids in assessing protein expression levels, subcellular localization, and interactions in various tissues or cell lines. Specificity is confirmed through knockdown/knockout controls or blocking assays.
Research utilizing SLC25A1 antibodies has advanced understanding of its role in metabolic reprogramming in cancers, such as its overexpression in tumors reliant on citrate for lipid biosynthesis. Additionally, studies link SLC25A1 mutations to severe developmental disorders, including combined D-2- and L-2-hydroxyglutaric aciduria. Commercial antibodies vary in host species (e.g., rabbit, mouse) and clonality, with selection depending on experimental needs. Proper validation ensures reliability in uncovering SLC25A1’s pathophysiological significance and therapeutic potential.
×
